Abalone Bio

Based in Emeryville, California, Abalone Bio is a preclinical biotechnology company that develops activating antibodies for hard-to-drug targets such as G protein-coupled receptors and ion channels. The enterprise utilizes its proprietary FAST platform, which combines engineered biology with artificial intelligence and machine learning, to measure the functional activity of millions of antibodies. This technology enables the discovery of therapeutics for complex conditions, including metabolic disorders, inflammatory bowel disease, obesity, and cancer, with lead programs like ABt140 advancing for endometriosis. Backed by Y Combinator, the 14-employee startup operates with under $10 million in early venture funding alongside $7 million awarded in non-dilutive Small Business Innovation Research grants. The firm generates capital through pharmaceutical partnerships, securing $3 million in upfront revenue and an estimated $125 million in potential downstream value. Abalone Bio was founded in 2018 by Richard Yu.

High-Level Overview

Abalone Bio is a biotechnology company specializing in the development of activating antibody drugs that target challenging and previously undruggable receptors on cell surfaces, particularly G-protein coupled receptors (GPCRs). Their proprietary Functional Antibody Selection Technology (FAST) platform enables the rapid discovery and optimization of antibodies that not only bind but *activate* these receptors, unlocking therapeutic potential in diseases others cannot effectively treat. Abalone Bio’s lead focus areas include inflammatory diseases, cancer, metabolic disorders such as obesity, and rare diseases like polycystic kidney disease. Their approach combines engineered living cells with AI/ML-driven high-throughput functional screening, allowing measurement of hundreds of millions of antibodies per experiment, vastly exceeding traditional methods[1][2][6].

As a portfolio company, Abalone Bio builds target-activating antibody therapeutics serving patients with diseases lacking effective treatments due to the difficulty of drugging GPCRs. Their technology addresses the problem of limited drug options for these receptors by enabling both activating and inhibiting antibodies, expanding therapeutic possibilities. The company has demonstrated growth momentum through multiple partnerships generating revenue and substantial downstream value, along with non-dilutive grant funding supporting platform and program development[2][4][5].

Origin Story

Founded in 2017 by Richard Yu (CEO) and Gustavo Pesce, Abalone Bio emerged from the founders’ complementary expertise in molecular biology, synthetic biology, and machine learning. They identified a critical unmet need: the lack of specific, functionally active drugs for GPCRs, which are involved in nearly every biological process but are notoriously difficult to target with antibodies. Their “a-ha” moment came from combining engineered biology with AI to create a large-scale functional antibody measurement platform, enabling discovery of rare activating antibodies. Early traction included successful development of antibody agonists for two of the few GPCRs ever drugged by biotech, seed funding from Y Combinator, and grant awards supporting their innovative platform[3][5][2].

Core Differentiators

• Functional Activity Measurement: Unlike conventional antibody discovery that focuses on binding, Abalone Bio’s FAST platform measures *functional activity* of antibodies at an unprecedented scale (100 million antibodies per experiment), enabling discovery of rare activating antibodies[6][2].

• Targeting GPCRs: They focus on GPCRs, the hardest class of targets for antibodies, requiring precise structural modulation rather than simple binding or inhibition[6].

• AI/ML Integration: Proprietary large-scale functional datasets power machine learning models that predict and optimize activating antibody sequences, a first in the field[6][2].

• Proven Platform: Demonstrated success with activating antibodies for multiple GPCR targets, with ongoing internal pipeline and pharma partnerships generating revenue and downstream value[2][6].

• Broad Therapeutic Scope: Programs span inflammatory diseases, cancer, metabolic disorders, rare kidney disease, and neuropathic pain, addressing significant unmet medical needs[1][7].

Role in the Broader Tech Landscape

Abalone Bio rides the convergence of engineered biology and artificial intelligence in drug discovery, a transformative trend enabling breakthroughs against previously undruggable targets. The timing is critical as GPCRs represent a vast, validated target class with limited antibody-based therapies due to technical challenges. Their ability to measure function at scale and leverage AI to design activating antibodies positions them at the forefront of next-generation biologics. Market forces favor such innovation given the high prevalence of diseases linked to GPCR dysfunction and the limitations of existing small molecule drugs. Abalone Bio’s platform and discoveries influence the biotech ecosystem by expanding the scope of antibody therapeutics and demonstrating the power of integrating functional screening with AI-driven design[6][2][3].

Quick Take & Future Outlook

Looking ahead, Abalone Bio is poised to expand its pipeline of activating antibody drugs across multiple high-impact disease areas, leveraging its unique platform and AI capabilities. Trends such as increased adoption of AI in biologics design, growing demand for safer, more effective therapies, and the push to drug challenging targets will shape their trajectory. Their influence may grow as they validate more targets, deepen pharma partnerships, and potentially bring first-in-class therapies to market. Abalone Bio exemplifies the future of antibody drug discovery—function-first, AI-enabled, and focused on unlocking therapies for diseases others cannot treat, fulfilling their mission to create activating antibodies that transform patient outcomes[2][6].